Aethlon Medical, Inc. (NASDAQ:AEMD) Short Interest Down 46.7% in March

Aethlon Medical, Inc. (NASDAQ:AEMD) saw a large drop in short interest during the month of March. As of March 15th, there was short interest totalling 255,400 shares, a drop of 46.7% from the February 28th total of 479,400 shares. Based on an average daily trading volume, of 3,140,000 shares, the days-to-cover ratio is presently 0.1 days. Approximately 1.8% of the shares of the company are short sold.

Aethlon Medical Trading Down 8.6 %

Shares of AEMD stock opened at $0.37 on Friday. Aethlon Medical has a twelve month low of $0.24 and a twelve month high of $1.79. The stock has a 50 day moving average of $0.56 and a 200 day moving average of $0.50. The stock has a market cap of $5.30 million, a P/E ratio of -0.23 and a beta of 1.80.

Aethlon Medical (NASDAQ:AEMD) last posted its earnings results on Wednesday, February 12th. The medical equipment provider reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.09. On average, research analysts predict that Aethlon Medical will post -0.73 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Renaissance Technologies LLC acquired a new position in shares of Aethlon Medical during the 4th quarter worth about $25,000. Allegiance Financial Group Advisory Services LLC purchased a new stake in Aethlon Medical during the 4th quarter worth approximately $26,000. Sassicaia Capital Advisers LLC acquired a new position in shares of Aethlon Medical during the fourth quarter valued at approximately $31,000. Virtu Financial LLC acquired a new position in shares of Aethlon Medical during the fourth quarter valued at approximately $81,000. Finally, Boothbay Fund Management LLC purchased a new position in shares of Aethlon Medical in the fourth quarter valued at approximately $186,000. Hedge funds and other institutional investors own 1.99% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently commented on AEMD. StockNews.com initiated coverage on shares of Aethlon Medical in a report on Friday. They issued a “sell” rating on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price target on shares of Aethlon Medical in a report on Monday, March 10th.

Aethlon Medical Company Profile

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.